What is the key player in TDP-43 pathology in ALS: Disappearance from the nucleus or inclusion formation in the cytoplasm?

Neurology and Clinical Neuroscience

Volumn 1, Issue 1, 2013, Pages 11-17

  Onodera, Osamu ^a   Sugai, Akihiro ^a   Konno, Takuya ^a   Tada, Mari ^a   Koyama, Akihide ^b   Nishizawa, Masatoyo ^a  

^a Niigata University   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; TDP 43

Indexed keywords

POLYGLUTAMINE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHROMOSOME 9; DNA STRUCTURE; GENE MUTATION; HEXANUCLEOTIDE REPEAT EXPANSION; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TDP 43 PROTEINOPATHY; UBIQUITINATION;

EID: 84891813509     PISSN: None     EISSN: 20494173     Source Type: Journal    
DOI: 10.1002/ncn3.9     Document Type: Article

References (70)

1. Arai T, Hasegawa M, Akiyama H et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006; 3: 602-11.
2. Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314(5796): 130-3.
3. Mackenzie IR, Bigio EH, Ince PG et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007; 61(5): 427-34.
4. Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch. Neurol. 2007; 64(10): 1388-94.
5. Tan CF, Eguchi H, Tagawa A et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007; 113(5): 535-42.
6. Mackenzie IRA, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010; 9(10): 995-1007.
7. Gitcho MA, Baloh RH, Chakraverty S et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008; 63(4): 535-8.
8. Kabashi E, Valdmanis PN, Dion P et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008; 40(5): 572-4.
9. Rutherford NJ, Zhang YJ, Baker M et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008; 4(9): e1000193.
10. Sreedharan J, Blair IP, Tripathi VB et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319(5870): 1668-72.
11. Van Deerlin VM, Leverenz JB, Bekris LM et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008; 7(5): 409-16.
12. Yokoseki A, Shiga A, Tan CF et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. Neurol. 2008; 63(4): 538-42.
13. Johnson JO, Mandrioli J, Benatar M et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68(5): 857-64.
14. Cairns NJ, Neumann M, Bigio EH et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007; 171(1): 227-40.
15. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72(2): 245-56.
16. Renton AE, Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72(2): 257-68.
17. Murray ME, DeJesus-Hernandez M, Rutherford NJ et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011; 122(6): 673-90.
18. Boeve BF, Boylan KB, Graff-Radford NR et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135(3): 765-83.
19. Majounie E, Renton AE, Mok K et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012; 11(4): 323-30.
20. Hsiung GY, DeJesus-Hernandez M, Feldman HH et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 2012; 135(3): 709-22.
21. Mackenzie IR, Neumann M, Baborie A et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011 l; 122(1): 111-3.
22. Tsuji H, Arai T, Kametani F et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012; 135(11): 3380-91.
23. Kuo PH, Doudeva LG, Wang YT, Shen CK, Yuan HS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009; 37(6): 1799-808.
24. Igaz LM, Kwong LK, Chen-Plotkin A et al. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J. Biol. Chem. 2009; 284(13): 8516-24.
25. Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum. Mol. Genet. 2009; 18(18): 3353-64.
26. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008; 283(19): 13302-9.
27. Igaz LM, Kwong LK, Lee EB et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 2011; 121(2): 726-38.
28. Mori F, Tanji K, Zhang HX et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008; 116(2): 193-203.
29. Hasegawa M, Arai T, Nonaka T et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008; 64(1): 60-70.
30. Igaz LM, Kwong LK, Xu Y et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am. J. Pathol. 2008; 173(1): 182-94.
31. Inukai Y, Nonaka T, Arai T et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008; 582(19): 2899-904.
32. Zhang YJ, Xu YF, Cook C et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 2009; 106(18): 7607-12.
33. Guo W, Chen Y, Zhou X et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Structl. Mol. Biol. 2011; 18(7): 822-30.
34. Zhou H, Huang C, Chen H et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 2010; 6(3): e1000887.
35. Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J. Neurochem. 2011; 116(2): 248-59.
36. Nishimura AL, Zupunski V, Troakes C et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 2010; 133(6): 1763-71.
37. Colombrita C, Zennaro E, Fallini C et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 2009; 111(4): 1051-61.
38. Kabashi E, Lin L, Tradewell ML et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010; 19(4): 671-83.
39. Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann Neurol. 2011; 69(1): 152-62.
40. Polymenidou M, Lagier-Tourenne C, Hutt KR et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011; 14(4): 459-68.
41. Tollervey JR, Curk T, Rogelj B et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011; 14(4): 452-8.
42. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 2005; 280(45): 37572-84.
43. D'Ambrogio A, Buratti E, Stuani C et al. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 2009; 37(12): 4116-26.
44. Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome. Res. 2010; 9(2): 1104-20.
45. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 2010; 30(2): 639-49.
46. Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum. Mol. Genet. 2011; 20(12): 2308-21.
47. Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J. Neurosci. 2010; 30(48): 16208-19.
48. Vaccaro A, Tauffenberger A, Aggad D, Rouleau G, Drapeau P, Parker JA. Mutant TDP-43 and FUS cause age-dependent paralysis and neurodegeneration in C. elegans. PLoS ONE 2012; 7(2): e31321.
49. Tsao W, Jeong YH, Lin S et al. Rodent models of TDP-43: recent advances. Brain Res. 2012; 1462: 26-39.
50. Sephton CF, Good SK, Atkin S et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J. Biol. Chem. 2010; 285(9): 6826-34.
51. Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010; 40(2): 404-14.
52. Swarup V, Phaneuf D, Bareil C et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011; 134(9): 2610-26.
53. Tsai KJ, Yang CH, Fang YH et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J. Exp. Med. 2010; 207(8): 1661-73.
54. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 2009; 106(44): 18809-14.
55. Wils H, Kleinberger G, Janssens J et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 2010; 107(8): 3858-63.
56. Xu YF, Gendron TF, Zhang YJ et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010; 30(32): 10851-9.
57. Xu YF, Zhang YJ, Lin WL et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011; 6: 73.
58. Avendano-Vazquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012; 26(15): 1679-84.
59. Ayala YM, De Conti L, Avendano-Vazquez SE et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011; 30(2): 277-88.
60. Ni JZ, Grate L, Donohue JP et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007; 21(6): 708-18.
61. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 2007; 446(7138): 926-9.
62. Romero PR, Zaidi S, Fang YY et al. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc. Natl Acad. Sci. USA 2006; 103(22): 8390-5.
63. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem. Sci. 2008; 33(8): 385-93.
64. Ling SC, Albuquerque CP, Han JS et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl Acad. Sci. USA 2010; 107(30): 13318-23.
65. Kasai T, Tokuda T, Ishigami N et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009; 117(1): 55-62.
66. Noto Y, Shibuya K, Sato Y et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph. Lateral. Scler. 2011; 12(2): 140-3.
67. Steinacker P, Hendrich C, Sperfeld AD et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 2008; 65(11): 1481-7.
68. Rabin SJ, Kim JM, Baughn M et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. Hum. Mol. Gen. 2010; 19(2): 313-28.
69. Bilican B, Serio A, Barmada SJ et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl Acad. Sci. USA 2012; 109(15): 5803-8.
70. Egawa N, Kitaoka S, Tsukita K et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012; 4(145): 145ra104.